Announcement on Authorizing the Chairman to Decide on Entrusting Financial Management
Release time:
2020-08-05
证券简称:尖峰集团 证券代码:600668 编号:临2018-007
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于授权董事长决定委托理财的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
●委托理财金额:授权董事长行使不超过人民币3亿元的委托理财的决策权,在该额度内资金可以滚动使用,但任一时点存续的委托理财余额合计不得超过3亿元。
●委托理财投资类型:选择安全性高、流动性好、低风险的品种开展委托理财业务。
●委托理财期限:每笔投资业务的期限均不得超过12个月。
一、概述
(一)基本情况
1、原则:以“规范运作、防范风险、谨慎投资、保值增值”为原则。
2、品种:选择安全性高、流动性好、低风险的品种开展委托理财业务。
3、资金:自有资金。
4、授权额度、期限:授权董事长行使不超过人民币3亿元的委托理财的决策权,在该额度内资金可以滚动使用,但任一时点存续的委托理财余额合计不得超过3亿元。每笔委托理财的期限不得超过 12个月。授权期限自公司本次董事会审议通过之日起3年内有效。具体投资活动由公司财务部负责组织实施。
5、实施方式:授权董事长决定在上述额度内的委托理财投资相关事宜,包括但不限于:选择合格专业理财机构、选择具体的委托理财产品品种、明确委托理财金额及期限、签署相关合同及协议等。
(二)公司内部需履行的审批程序
2018年4月20日,公司第十届董事会第三次会议审议通过了《关于授权公司董事长利用自有资金进行委托理财的议案》。表决结果:同意9票、反对0票、弃权0票。
二、主要内容
(一)委托资金来源:自有资金。
(二)对公司的影响
1、公司的委托理财,是在确保公司日常运营和资金安全的前提下实施的,不影响公司日常资金周转,不影响公司经营业务的正常开展。
2、通过进行适度的低风险的理财产品投资业务,可以提高资金使用效率,能获得一定的投资效益,为公司股东谋取更多的投资回报。
(三)风险控制分析
公司严格按照《委托理财管理制度》审批和执行程序,确保委托理财等投资业务的有效开展和规范运行。但由于金融市场受经济环境的影响较大,不排除投资理财等投资业务会受到市场波动的影响,公司将采取以下措施:
(1)公司明确专人负责该等投资事项的相关工作:公司董事长行使该等投资决策权并签署相关合同文件,公司财务负责人负责组织实施,财务部负责具体操作。
(2)公司财务部负责及时分析和跟踪理财产品投向、投资项目进展情况,如评估发现存在可能影响公司资金安全或影响正常资金流动需求的状况,将及时采取相应保全或赎回措施,以控制投资风险。
(3)公司审计部门负责对各项投资情况进行审计与监督,定期对委托理财的进展情况、盈亏情况、风险控制等情况进行审计、核实,并根据谨慎性原则对各项委托理财可能的风险与收益进行评价,向董事会审计委员会报告。
(4)公司严格按照中国证监会及上海证券交易所的相关规定履行信息披露义务。
(四)独立董事意见
公司独立董事对该项决议发表了独立意见,认为:该决议的形成符合《公司法》、公司《章程》等有关规定,没有损害中小股东的利益。
三、截至本公告日,公司累计委托理财的情况
|
序号 |
受托人 |
理财产品类型 |
金额 (万元) |
起始日 |
到期日 |
截止公告日已收回本金金额(万元) |
截止公告日获得收益(万元) |
|
1 |
广发银行金华分行 |
薪加薪16号5876人民币结构性存款产品 |
5,000.00 |
2017/4/6 |
2017/7/5 |
5,000.00 |
51.16 |
|
2 |
渤海银行金华分行 |
渤海银行S17180号结构性存款理财产品 |
3,000.00 |
2017/5/17 |
2017/6/19 |
3,000.00 |
10.58 |
|
3 |
渤海银行金华分行 |
渤海银行S17265号结构性存款理财产品 |
3,000.00 |
2017/6/23 |
2017/7/27 |
3,000.00 |
12.30 |
|
4 |
广发银行金华分行 |
薪加薪16号J0253人民币结构性存款产品 |
4,000.00 |
2017/7/6 |
2017/10/9 |
4,000.00 |
44.66 |
|
5 |
广发银行金华分行 |
薪加薪16号J352人民币结构性存款产品 |
4,000.00 |
2017/7/28 |
2017/11/13 |
4,000.00 |
50.66 |
|
6 |
广发银行金华分行 |
薪加薪16号XJXCKJ0577人民币结构性存款产品 |
4,000.00 |
2017/9/14 |
2017/11/29 |
4,000.00 |
36.06 |
|
7 |
招商银行金华江北支行 |
招商银行结构性存款CHZ00318 |
3,000.00 |
2017/10/10 |
2017/11/13 |
3,000.00 |
10.76 |
|
8 |
渤海银行金华分行 |
渤海银行S17480号结构性存款理财产品 |
4,000.00 |
2017/10/12 |
2017/11/14 |
4,000.00 |
14.36 |
|
9 |
民生银行金华分行 |
与利率挂钩的结构性存款产品 |
3,000.00 |
2018/1/5 |
2018/2/14 |
3,000.00 |
14.79 |
|
10 |
渤海银行金华分行 |
渤海银行S17686号结构性存款理财产品 |
3,000.00 |
2018/1/9 |
2018/2/12 |
3,000.00 |
12.27 |
|
11 |
招商银行金华江北支行 |
招商银行结构性存款CHZ00473号 |
3,000.00 |
2018/4/3 |
2018/5/28 |
|
|
|
12 |
广发银行金华分行 |
薪加薪16号人民币结构性存款产品 |
4,000.00 |
2018/4/3 |
2018/5/28 |
|
|
|
13 |
渤海银行金华分行 |
渤海银行S18283号结构性存款理财产品 |
3,000.00 |
2018/4/4 |
2018/5/29 |
|
|
|
14 |
招商银行金华江北支行 |
招商银行结构性存款CHZ00483号 |
More information
The company fully deploys 2018 work
On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-30
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise
On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31